The changing consumer taste along with the changing lifestyle propel further growth in the Global Irritable Bowel Syndrome (IBS) Market
The Irritable Bowel Syndrome (IBS) market is expected to grow at a CAGR of 8.10% to reach $3,012 million, in 2030.
Covid-19 Impact & Market Status
The COVID-19 pandemic has projected an increase in mental distress and ascent of gastrointestinal symptoms among people. The resultant effect is because high anxiety and stress prompt physiological comorbidities. Developing reception of online distribution channels by key makers has affected revenue generation as well as sales of products. This is facilitated by higher item reach as well as expanding awareness among everyone in regards to the side effects connected with irritable bowel syndrome.
IBS with diarrhea (IBS-D) to Emerge as the Most Lucrative Segment
The IBS with diarrhea (IBS-D) portion gained the biggest irritable bowel syndrome treatment gained the market in 2020. Besides, this section is likewise expected to encounter development at the quickest rate during the conjecture time frame, attributable to increment in the predominance of gastrointestinal sicknesses, for example, obstruction and the runs because of progress in ways of life, expansion in geriatric populace, flood in take-up of medications, for example, linaclotide and lubiprostone, and ascend in persistent awareness toward the therapy of irritable bowel syndrome gut condition.
Rifaximin to Ensure Revenue Maximization
As per product, the rifaximin fragment produced the most noteworthy income in 2020 and is supposed to keep up with its strength all through the estimated period. This is credited to increment in the predominance of irritable bowel syndrome, the surge in the adoption of the irritable bowel syndrome products, ascend in geriatric populace, expansion in awareness toward crabby gut condition and further developed determination, and development of technologically advanced treatment products that have driven the interest for the utilization of touchy gut condition treatment market products around the world.
Backed by Immense Development Potential Asia-Pacific Irritable Bowel Syndrome (IBS) Market to Sail Ahead
Asia-Pacific presents worthwhile opportunities for the key players working in the irritable bowel syndrome gut disorder treatment market, developing awareness in regards to the treatment of irritable bowel syndrome. In addition, improvement in medical services framework, rise in the number of clinics outfitted with cutting-edge clinical offices, the developing R&D area, ascend in medical services changes, and mechanical progressions in the field of medical care further add to the market development. A few different factors, for example, the surge in the focus of the leading manufacturers on extending their geographic presence in arising Asia-Pacific nations to catch high learning experiences on the lookout, high populace base, and high dispensable wages are supposed to drive the development of the irritable bowel syndrome treatment market in Asia-Pacific.
The rising cases of irritable bowel syndrome (IBS) due to the consumption of packaged food to ravel the market
The global market size of IBS market (irritable bowel syndrome) by 2029 is anticipated to hit over USD 2.32 billion at a CAGR of 8.2 % during the projection timeline, 2022-2029.
IBS (Irritable Bowel Syndrome) affects many and disrupts the quality of life of people globally. The disease mainly targets the large intestinal area and triggers unbearable pain, in the abdomen, constipation, and diarrhea among others. As the condition becomes chronic, it is important to ensure early detection and management to maintain the quality of life among patients. Growing consciousness about the symptoms among people, advances in the therapeutic approach, and growing patient pools are steering high ned growth in the global irritable bowel syndrome market in recent times. IBS is identified to have three variants, such as with diarrhea, diarrhea and mixed conditions.
Treatment of Irritable bowel syndrome comprises pressure alleviation, change in diet, appropriate drugs, and counseling. SOme of the commonly prescribed medications for irritable bowel syndrome condition comprises lubiprostone, rifaximin, linaclotide, and eluxadoline among others. However, an alternative approach is also common which includes Peppermint, hyoscyamine, and dicyclomine.
The rise in the geriatric population, expansion in the pervasiveness of gastrointestinal sicknesses and problems, for example, changes in bowel habits and abdominal pain, the surge in the level of stress, and unfortunate eating routine are the central points that drive the development of the peevish gut disorder therapy market. Moreover, expansion in awareness programs in regards to the treatment and the executives of irritable bowel syndrome gut condition and surge in the tendency toward IBS products that upgrade remedial results are different elements that contribute toward the development of the market. However, with ample opportunities emerging in the developing world, on the back of improved healthcare system, patient awareness, and availability of generic medicines are definitely aiding in market progression. Notwithstanding, the absence of explicit treatment that treats every one of the side effects of the IBS problem and high contest among the central participants connected with valuing are supposed to limit the development of the market.
Among all other established and emerging companies and investors. These frontline players have a strong foothold globally and are investing aggressively towards developing growth proficient business strategies. Besides the organic and inorganic growth investments, R&D development is also claiming a major investment chunk to ensure breakthroughs in medical approach and care delivery.
Latest Innovations: Irritable Bowel Syndrome Market
In August 2021, a team of researchers from The Technical University of Munich, under the leadership of Prof. SChemann has come up with new findings in biomarkers that could lend a breakthrough in the current treatment approaches for Irritable Bowel Syndrome (IBS).
Irritable Bowel Syndrome (IBS) Market Scope
|Forecast Unit||Value (USD)|
|Revenue forecast in 2028||USD 2.32 billion|
|Growth Rate||CAGR of 8.2 % during 2021-2028|
|Segment Covered||Type, Product, Regions|
|Regions Covered||North America, Europe, Asia Pacific, Middle East and Africa, South America|
|Key Players Profiled||Abbott Laboratories, Allergan plc, Ardelyx Inc., Astellas Pharma Inc., AstraZeneca plc, GlaxoSmithKline Plc, Johnson & Johnson (McNeil Consumer Healthcare), Novartis AG, Sebela Pharmaceuticals Inc., Takeda Pharmaceutical Company Ltd. & among others.|
Key Segments of the Global Irritable Bowel Syndrome (IBS) Market
Type Overview, 2019-2029 (USD million)
- IBS with Diarrhea (IBS-D)
- IBS with Constipation (IBS-C)
- Mixed-presentation IBS (IBS-M)
Product Overview, 2019-2029 (USD million)
Regional Overview, 2019-2029 (USD million)
- Rest of Europe
- Rest of Asia Pacific
- Rest of South America
The Middle East and South Africa